ABCC8 Gene NGS Panel for Noninsulin-Dependent Diabetes Mellitus (Type 2 Diabetes) – Dubai, UAE | 2,800 AED

Executive Summary & Core Metrics

The ABCC8 gene Next-Generation Sequencing (NGS) panel delivers 99.9% diagnostic sensitivity for detecting pathogenic variants linked to noninsulin-dependent diabetes mellitus. Conducted at our ISO-certified laboratory in Dubai Healthcare City, this test enables precise risk stratification, differentiation of monogenic diabetes from common type 2 diabetes, and personalised treatment planning. The service includes VIP mobile phlebotomy with temperature-controlled cold-chain home collection, direct insurance verification via WhatsApp (+971 54 548 8731), and a post-result teleconsultation to interpret clinical implications.

Test Overview & Methodology

The ABCC8 gene encodes the sulfonylurea receptor (SUR1), a critical regulator of insulin secretion from pancreatic beta cells. Pathogenic variants in ABCC8 impair glucose-dependent insulin release, increasing susceptibility to type 2 diabetes and maturity-onset diabetes of the young (MODY). This comprehensive NGS panel sequences all coding regions and splice sites, detecting known and novel variants with orthogonal validation to ensure clinical accuracy.

Parameter	Our ABCC8 NGS Test	Closest Alternative (Sanger Single‑Site)
Analytical Precision	99.9% diagnostic sensitivity, complete gene coverage	Targeted variant only; may miss novel mutations
Methodology	Next‑Generation Sequencing (NGS) with orthogonal validation	Sanger sequencing of a single exon or pre‑defined variant
Turnaround Time	3–4 weeks (from sample receipt)	2–3 weeks for limited targets

Physician Insight & Safety Protocols

“This NGS panel provides a thorough evaluation of the ABCC8 gene to clarify diabetes aetiology and guide evidence‑based therapy. A detected pathogenic variant indicates elevated genetic risk, not a definitive diagnosis, and must be correlated with fasting glucose, HbA1c, and family history. I strongly recommend collaborative interpretation with your endocrinologist to integrate these findings into a holistic care plan.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Medication Safety Advisory

⚠️ Do Not Discontinue Prescribed Medication

Do not alter or stop current diabetes medications without consulting your physician. Genetic results may influence future therapy, but immediate changes require clinical oversight to avoid metabolic complications.

Patient Exclusion Criteria & Red Flags

Exclusion Criteria for Sample Collection

Acute febrile illness (temperature >38°C) or active systemic infection — collection should be postponed until full recovery.
Current use of anticoagulant or antiplatelet therapy without prior physician clearance may increase haematoma risk at the venipuncture site.
Significant coagulopathy (INR >1.5, platelet count <80×10⁹/L) precludes routine phlebotomy; contact the laboratory for alternate sampling arrangements.
Inadequate venous access due to severe dehydration or difficult anatomy — a senior phlebotomist must evaluate suitability.

Emergency Red Flags After Sample Collection

Signs of anaphylaxis (rash, lip swelling, difficulty breathing, hypotension) — seek immediate emergency care.
Uncontrolled hyperglycaemia with nausea, vomiting, or fruity breath odour (possible diabetic ketoacidosis) — proceed to the nearest emergency department.
Sudden loss of consciousness or profound dizziness — call 998 immediately.

Patient FAQ & Clinical Guidance

1. What is the ABCC8 gene and how does it influence diabetes risk?

The ABCC8 gene encodes the sulfonylurea receptor SUR1, which directly regulates insulin secretion from pancreatic beta cells. Pathogenic variants can impair glucose-stimulated insulin release, elevating the risk for type 2 diabetes and maturity-onset diabetes of the young (MODY). This NGS test sequences the entire coding region to identify such variants, helping distinguish monogenic from polygenic forms of diabetes and guiding optimal therapy—for example, sulfonylurea responsiveness in certain ABCC8 mutation carriers. Genetic counselling before and after testing is recommended to interpret family implications.

2. Can this genetic test alone confirm a diabetes diagnosis?

No. Genetic testing identifies susceptibility variants and can confirm monogenic diabetes subtypes, but it is not a standalone diagnostic tool. Results must be interpreted alongside clinical markers such as fasting plasma glucose, HbA1c, C-peptide, autoantibodies, and family history. A negative genetic result does not exclude diabetes caused by environmental or polygenic factors, while a positive finding warrants ongoing surveillance and lifestyle management. Always integrate genetic data with your physician’s comprehensive assessment.

3. What sample is required and how is the home collection service arranged?

A peripheral whole blood sample or DNA FTA card is collected by a certified phlebotomist at your location using a sterile kit. The service operates daily from 8 AM to 11 PM, with temperature-controlled cold-chain transport to our ISO-certified facility. After booking via WhatsApp, the phlebotomist arrives with all necessary equipment. For standard venipuncture, a single blood draw is collected in EDTA tubes; the FTA card method requires a simple finger prick. Samples are tracked through the logistics chain, and results are delivered within 3–4 weeks.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance & Data Protection Framework

This service operates under the governance of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring that all patient genetic and clinical data are processed, stored, and transmitted with strict confidentiality and security measures. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and holds DHA Facility License 1143.

Clinical & Logistical Metadata

Test Name	ABCC8 Gene NGS Panel for Noninsulin-Dependent Diabetes Mellitus (Type 2 Diabetes)
Price (AED)	2,800
Turnaround Time	3–4 weeks from sample receipt
Sample Type / Matrix	Peripheral Whole Blood (EDTA) or DNA FTA Card – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily 8 AM – 11 PM)
Methodology Used	Next-Generation Sequencing (NGS) with Orthogonal Validation
ICD-10-CM Code	E11.9
LOINC Code	21621-4
DHA Facility License & Laboratory Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE